Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma,…
| Periodo | 2027-03 | 2022-04 | 2022-04 | 2022-04 |
|---|---|---|---|---|
| Real | — | $-0.16 | $-0.20 | $-0.16 |
| Estimado | — | $-0.59 | $-1.05 | $-0.45 |
| Sorpresa | — | +72.9% | +81.0% | +64.4% |
| Métrica | NBTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | -33.2% | -34.4% | +1.2% |
| Net Margin | -73.5% | -32.5% | -41.1% |
| FCF Margin | -104.2% | -12.6% | -91.6% |
| ROE | — | -39.2% | — |
| ROA | -35.4% | -30.9% | -4.4% |
| Current Ratio | 1.09 | 2.73 | -1.64 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -35.4% | — |
| ✗Flujo de caja operativo positivo | −€33M | −€20M |
| ✓Rentabilidad sobre activos al alza | -35.4% | -101.1% |
| ✗Caja operativa/activos supera al ROA | -49.3% | ROA -35.4% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 1.09 | 1.04 |
| ✗Sin aumentar el nº de acciones | 48M | 47M |
| –Margen bruto al alza | — | — |
| ✓Rotación de activos al alza | 0.48 | -0.11 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -104.2% |
| ✗ROCE > 10 % | -105.5% |
| ✓Ventas > 5 %/año (3 años) | 89.7% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 72.6% |
Nanobiotix S.A. cotiza a 21.30 USD y tiene una capitalización bursátil de $1.1B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud